Denosumab Demonstrated Superiority Over Zometa In Pivotal Phase 3 Head-To-Head Trial In Prostate Cancer Patients With Bone Metastases

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Amgen announced that a pivotal, Phase 3, head-to- head trial evaluating denosumab versus Zometa (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.